Dr. Nancy R. Foldvary-schaefer, DO
Sleep Medicine (Sleep Medicine (Psychiatry & Neurology) Physician)
- Medicare participating
At a glance
- Medical school
- Chicago College of Osteopathy (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 179
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: Chicago College of Osteopathy
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Sleep Medicine (Psychiatry & Neurology) Physician primary
OH license 34006241F -
Neurology Physician
OH license 34006241F
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Cleveland, OH
- Hillcrest Hospital Mayfield Heights, OH
- Medina Hospital Medina, OH
Medical groups
- Cleveland Clinic (7,090 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 179
- Services billed
- 300
- Patients’ average age
- 67
| Service | Times | Patients |
|---|---|---|
| Sleep study including heart rate, breathing, airflow, and effort | 50 | 49 |
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 47 | 19 |
| Established patient office or other outpatient visit, 20-29 minutes | 47 | 42 |
| Sleep study in sleep lab (6 years or older) | 35 | 35 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 28 | 28 |
| Established patient office or other outpatient visit, 30-39 minutes | 25 | 19 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 15 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Lamotrigine Other prescribers in Cleveland, OH | 38 |
| Zonisamide Other prescribers in Cleveland, OH | 23 |
| Modafinil Other prescribers in Cleveland, OH | 23 |
| Zolpidem Tartrate Other prescribers in Cleveland, OH | 22 |
| Xywav (sodium,calcium,mag,pot oxybate) | 22 |
| Clobazam | 21 |
| Vyvanse (lisdexamfetamine dimesylate) Other prescribers in Cleveland, OH | 21 |
| Levetiracetam Other prescribers in Cleveland, OH | 20 |
| Gabapentin Other prescribers in Cleveland, OH | 19 |
| Onfi (clobazam) | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 42 payments worth $46,993 in total to this clinician.
| Jazz Pharmaceuticals Inc. | $33,353 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $13,641 |
| Consulting Fee | $30,903 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $10,498 |
| Travel and Lodging | $4,766 |
| Food and Beverage | $826 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. Jul 2, 2025 | Consulting Fee XYWAV · NEUROLOGY | $18,669 |
| Jazz Pharmaceuticals Inc. Jan 21, 2025 | Compensation for services other than consulting (speaking, faculty) XYWAV · NEUROLOGY | $9,779 |
| Takeda Pharmaceuticals U.S.A., Inc. Dec 6, 2025 | Consulting Fee | $9,345 |
| Jazz Pharmaceuticals Inc. May 7, 2025 | Consulting Fee XYWAV · NEUROLOGY | $2,889 |
| Jazz Pharmaceuticals Inc. Jun 5, 2025 | Travel and Lodging XYWAV · NEUROLOGY · travel to Seattle, WA · in-kind | $767 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 21, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $719 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $719 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 20, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $492 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 20, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $492 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 21, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $427 |
All 20 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Dec 6, 2025 | Consulting Fee | $9,345 |
| Takeda Pharmaceuticals U.S.A., Inc. Dec 6, 2025 | Travel and Lodging travel to ROSEMONT, IL · in-kind | $308 |
| Takeda Pharmaceuticals U.S.A., Inc. Dec 6, 2025 | Travel and Lodging travel to ROSEMONT, IL · in-kind | $227 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 20, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $492 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 20, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $492 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 20, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $80.68 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 20, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $80.68 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 20, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $31.98 |
| Takeda Pharmaceuticals U.S.A., Inc. Nov 20, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $31.98 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 22, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $342 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 22, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $85.00 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 21, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $719 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $719 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 21, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $427 |
| Jazz Pharmaceuticals Inc. Jul 2, 2025 | Consulting Fee XYWAV · NEUROLOGY | $18,669 |
| Jazz Pharmaceuticals Inc. Jun 6, 2025 | Travel and Lodging XYWAV · NEUROLOGY · travel to Seattle, WA · in-kind | $341 |
| Jazz Pharmaceuticals Inc. Jun 5, 2025 | Travel and Lodging XYWAV · NEUROLOGY · travel to Seattle, WA · in-kind | $767 |
| Jazz Pharmaceuticals Inc. Jun 5, 2025 | Travel and Lodging XYWAV · NEUROLOGY · travel to Seattle, WA · in-kind | $341 |
| Jazz Pharmaceuticals Inc. May 7, 2025 | Consulting Fee XYWAV · NEUROLOGY | $2,889 |
| Jazz Pharmaceuticals Inc. Jan 21, 2025 | Compensation for services other than consulting (speaking, faculty) XYWAV · NEUROLOGY | $9,779 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $585,501 in research payments for these studies, mostly to the institutions running them.
- A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Y…
Jazz Pharmaceuticals Inc. - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2
Alkermes, Inc. · Completed · NCT06555783 - TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy
Takeda Pharmaceuticals U.S.A., Inc. - A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia
Alkermes, Inc. · Recruiting · NCT06767683 - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
Alkermes, Inc. · Completed · NCT06358950 - A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia
Alkermes, Inc. · Active, not recruiting · NCT06843590 - A long-term extension study to evaluate the safety and tolerability of TAK-861 in participants with selected central hypersomnia conditions
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.